Abaloparatide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •2 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
In rodent studies, PTH1R agonists caused dose-dependent osteosarcoma at high doses over near-lifetime exposure. Human relevance is considered low. The teriparatide boxed warning was removed in 2020 after 18 years of surveillance. Abaloparatide remains contraindicated in patients with increased baseline osteosarcoma risk.
Abaloparatide transiently elevates serum calcium (3.4% incidence in ACTIVE trial). Generally mild and asymptomatic, resolving within 16-24 hours. Monitor serum calcium, particularly with concomitant digoxin or thiazide diuretics.
⚠️Important Warnings
- •Osteosarcoma risk: Contraindicated in patients at increased risk for osteosarcoma including those with Paget disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior external beam or implant radiation therapy involving the skeleton.
- •Hypercalcemia: Monitor serum calcium. Use caution in patients with pre-existing hypercalcemia or conditions predisposing to hypercalcemia.
- •Orthostatic hypotension: Transient decreases in blood pressure may occur shortly after injection. Administer where the patient can sit or lie down if symptoms occur.
- •Pregnancy: May cause fetal harm based on animal data. Use effective contraception during treatment.
- •Treatment duration: Recommended for up to 2 years of cumulative use based on clinical trial duration.
- •Sequential therapy: Follow abaloparatide with antiresorptive therapy to maintain BMD gains. BMD may decline rapidly if no consolidation therapy is initiated.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Prescription | FDA-approved as Tymlos in April 2017 for postmenopausal osteoporosis at high fracture risk. Expanded in January 2023 to include men with osteoporosis at high fracture risk. Prescription only; not a controlled substance. Marketed by Ipsen. |
| European Union | Prescription | Not approved by EMA. Abaloparatide was withdrawn from the EMA application process. Not available in EU member states. |
| Canada | Prescription | Approved by Health Canada for treatment of osteoporosis in postmenopausal women at high risk of fracture. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 35+ community reports
View community protocolsCritical Safety Information#
Abaloparatide (Tymlos) is an FDA-approved prescription medication with a safety profile established through the ACTIVE phase 3 trial (n=2,463), ACTIVExtend extension study, and post-marketing surveillance since April 2017. This page provides a comprehensive overview of known risks, regulatory status, and population-specific warnings.
Osteosarcoma Risk#
Preclinical Evidence#
In rodent carcinogenicity studies, PTH1R agonists (including teriparatide) caused dose-dependent increases in osteosarcoma in Fischer 344 rats at doses exceeding clinical exposure and over near-lifetime treatment durations. This is a class effect related to sustained PTH1R activation in a species with continuous skeletal growth and no osteonal bone remodeling.
Relevance to Humans#
The osteosarcoma risk observed in rats is considered to have low human relevance because:
- Human and primate bone undergoes remodeling rather than continuous growth
- The doses and durations used in rat studies substantially exceed clinical use
- Over 20 years of teriparatide post-marketing surveillance have not identified increased osteosarcoma risk in humans
- The FDA removed the teriparatide osteosarcoma boxed warning in 2020
Clinical Implications#
Despite the low human relevance, abaloparatide is contraindicated in patients at increased baseline risk for osteosarcoma:
- Paget disease of bone
- Unexplained elevations of alkaline phosphatase
- Open epiphyses (pediatric and adolescent patients)
- Prior external beam or implant radiation therapy involving the skeleton
Hypercalcemia#
Abaloparatide transiently increases serum calcium through PTH1R-mediated effects. In the ACTIVE trial, hypercalcemia was reported in 3.4% of patients (versus 6.4% with teriparatide and 0.4% with placebo). Elevated calcium is typically transient, peaking 4-6 hours post-injection and resolving within 16-24 hours. Symptomatic hypercalcemia requiring treatment discontinuation is rare.
Orthostatic Hypotension#
Transient decreases in blood pressure may occur shortly after abaloparatide injection. Patients should be counseled to administer injections where they can sit or lie down if dizziness, lightheadedness, or palpitations occur. This effect is most common during the initial doses.
Bone Loss After Discontinuation#
If abaloparatide is discontinued without transitioning to an antiresorptive agent, BMD gains may be rapidly lost. The ACTIVExtend trial demonstrated that sequential therapy with alendronate preserves and consolidates BMD gains. Patients should not discontinue abaloparatide without a plan for antiresorptive consolidation.
Regulatory and Legal Status#
Abaloparatide is a prescription medication in all jurisdictions where approved. It is not a controlled substance.
| Jurisdiction | Status | Brand Name | Approved Indications |
|---|---|---|---|
| United States (FDA) | Approved (2017) | Tymlos | PMO (2017), male OP (2023) |
| Canada (Health Canada) | Approved | Tymlos | Postmenopausal osteoporosis |
| European Union (EMA) | Not approved | N/A | Application withdrawn |
| Japan (PMDA) | Approved (2024) | Ostaballo | Osteoporosis |
At-Risk Populations#
Patients with Paget Disease or Skeletal Malignancy Risk#
Absolute contraindication due to theoretical osteosarcoma risk from sustained osteoblast stimulation.
Pregnant Women#
Abaloparatide demonstrated embryo-fetal toxicity in animal studies at doses exceeding clinical exposure. Women of childbearing potential should use effective contraception during treatment. Discontinue abaloparatide if pregnancy is confirmed.
Patients with Renal Impairment#
Not studied in severe renal impairment (eGFR <30 mL/min). Use with caution due to impaired calcium handling in severe CKD.
Patients on Digoxin#
Abaloparatide-induced hypercalcemia may predispose to digitalis toxicity. Monitor serum calcium and digoxin levels closely.
Risk Mitigation#
For Prescribers#
- Screen for Paget disease and unexplained alkaline phosphatase elevation before prescribing
- Check baseline serum calcium; do not initiate if hypercalcemic
- Ensure adequate vitamin D repletion before starting therapy
- Plan sequential antiresorptive therapy at the time of initiating abaloparatide
- Monitor serum calcium periodically during treatment
- Counsel patients on injection site rotation and orthostatic precautions
For Patients#
- Inject at the same time each day in the periumbilical region
- Sit or lie down if dizziness occurs after injection
- Take calcium and vitamin D supplements as directed
- Report symptoms of hypercalcemia (nausea, vomiting, constipation, lethargy, muscle weakness)
- Do not stop treatment without discussing antiresorptive transition with healthcare provider
- Use effective contraception if of childbearing potential
Related Reading#
Frequently Asked Questions About Abaloparatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.